ZipBio and MeiraGTx Partner to Develop AI-Designed Gene Therapy for Geographic Atrophy
核心洞察
ZipBio (搜索) and MeiraGTx announced an exclusive licensing agreement for first-in-class AAV gene therapies targeting geographic atrophy (搜索) through the complement pathway (搜索).
The partnership combines MeiraGTx's expertise in genetic medicines and manufacturing with ZipBio (搜索)'s COMPACT™ (搜索) AI platform for designing novel protein therapeutics.
The agreement includes upfront payments plus milestone and royalty payments, though specific financial terms were not disclosed.
ZipBio (搜索), a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX) to advance first-in-class AAV gene therapies for geographic atrophy (搜索). The partnership targets the complement pathway (搜索), representing a novel approach to treating this progressive retinal disease with significant unmet medical needs.
Strategic Partnership Combines AI and Gene Therapy Expertise
The licensing deal leverages the complementary strengths of both companies, combining MeiraGTx's leadership in vector design, clinical development, and in-house manufacturing of genetic medicines with ZipBio (搜索)'s expertise in de novo-designed protein therapeutics. Under the agreement, MeiraGTx receives exclusive rights to ZipBio's first-in-class therapies for geographic atrophy (搜索), with financial terms including upfront payments as well as potential milestone and royalty payments, though specific amounts were not disclosed.
"MeiraGTx's expertise in development of best-in-class genetic medicines in ophthalmology makes them the ideal partner to bring our next generation AI-designed Geographic Atrophy (搜索) therapies to patients with a significant unmet need," said Roee Farber, MD, CEO of ZipBio (搜索). "This license agreement allows ZipBio to concentrate on advancing our internal pipeline in immunology and cardiovascular disease, while continuing to pioneer next-generation biologics designed to target disease pathways that have historically been challenging to address."
COMPACT™ Platform Enables Novel Therapeutic Design
ZipBio (搜索)'s proprietary COMPACT™ (搜索) generative AI platform represents a breakthrough in protein therapeutic design, enabling the creation of Zip® drugs (搜索) - compact, multifunctional, and logic-gated proteins that go beyond the limits of conventional biologics. The platform focuses on validated targets that have remained out of reach for existing drug modalities, addressing disease pathways that have been historically difficult to modulate.
Through COMPACT™ (搜索), ZipBio (搜索) has built a growing pipeline across multiple high-impact therapeutic areas, with the geographic atrophy (搜索) program representing one of several initiatives targeting previously undruggable pathways. The agreement highlights the growing role of AI-enabled biologics in accelerating drug discovery and delivering transformative therapies for diseases with significant unmet medical needs.
MeiraGTx's Manufacturing and Development Capabilities
MeiraGTx brings substantial infrastructure and expertise to the partnership as a vertically integrated, clinical-stage genetic medicines company with a broad pipeline featuring four late-stage clinical programs. The company has built comprehensive manufacturing capabilities in the industry, including two manufacturing facilities licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure.
The company's proprietary manufacturing platform process, developed over nine years based on more than 20 different viral vectors, offers leading yield and quality aspects with commercial readiness. MeiraGTx's programs use local delivery of small doses resulting in disease-modifying effects in both inherited and more common diseases, particularly in ophthalmology, Parkinson's disease, and radiation-induced xerostomia.
Strategic Focus on High-Impact Diseases
The partnership reflects both companies' commitment to developing therapies that tackle prevalent and impactful diseases. For ZipBio (搜索), the agreement enables focused advancement of its internal pipeline in immunology and cardiovascular disease while ensuring its geographic atrophy (搜索) program receives specialized development through MeiraGTx's ophthalmology expertise.
MeiraGTx has developed technology to apply genetic medicine to common diseases, increasing efficacy, addressing novel targets, and expanding access in large disease areas where unmet need remains high. The company's innovative approach includes optimization of capsids, promoters, and novel translational control elements to develop best-in-class, potent, safe viral vectors.